Phathom Pharmaceuticals (PHAT) Stock Price & Analysis

PHAT$6.06-0.17 -2.73%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$492.63MEnterprise value$445.13MRevenue (TTM)$274.88MMarket position—

Score

68
Bullish
Value
60
Quality
44
Growth
100

AI Analysis

Snapshot

Phathom Pharmaceuticals is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. Under the hood: revenue compounding ~4109% annually over recent years. Street targets still imply ~172% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

60
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

44
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Phathom Pharmaceuticals, Inc. (PHAT) last printed $6.06. Equity value is $492.63M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$682,000.00$55.25M$175.11M

About

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Phathom Pharmaceuticals (PHAT) Stock Price & Analysis

PHAT price $6.06 -0.17 -2.73%

Ticker
PHAT
Price
$6.06
Change
-0.17 -2.73%
Market cap
$492.63M
Forward P/E
7.73
Dividend yield
0.00%
Beta
0.50
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
60
Quality
44
Growth
100

Stocklytics score rationale: value 60, quality 44, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener